News and Trends 12 Sep 2018 Airbus Will Use Recombinant Spider Silk to Build Lightweight Planes Airbus has signed a partnership with German biotech AMSilk for the development of a new biomaterial to be used in the construction of future high-performance planes. Spider silk is known for having outstanding strength and flexibility. AMSilk uses engineered bacteria to produce spider silk protein, which is then used to create materials with a wide […] September 12, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2018 Cambridge Biotech Targets Artificial Pancreas Market With Fast Insulin and Stable Glucagon UK biotech Arecor has raised €6.7M to help fund development of its extra-fast insulin and stable glucagon products for people with insulin-dependent diabetes. The speed of action of insulin has been a limiting factor for development of the artificial pancreas — a combined insulin pump and glucose monitor that would allow real-time control of blood […] September 10, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2018 Update: Non-Invasive Glucose Monitoring Device Moves Forward With Series B Funding Update (10/09/2018): RSP Systems has raised an additional €3.85M that raises the total amount of its Series B fundraising to €10.35M. The funds will be used to run clinical trials with the company’s device, which measures blood sugar without the need for finger-pricking. Published on 11/06/2018 RSP Systems has raised €6.5M in the first closing […] September 10, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2018 More Brexit Bad News: EMA Pulls Contracts Early From UK Regulatory Body The European Medicines Agency (EMA) has pulled all contracts with the UK’s medical regulation body ahead of the UK withdrawing from the EU next year. Until 2018, the EMA has relied on the UK Medicines & Healthcare products Regulatory Agency (MHRA) to assess 20–30% of its drugs on a contract basis, work worth approximately €15.6M […] September 6, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2018 Insulin Combo Reduces After-Meal Sugar Spikes in Type 1 Diabetics In the midst of a legal litigation with Eli Lilly, Adocia has released Phase 1 data showing its insulin combo can outperform Lilly’s fast-acting insulin in keeping sugar levels low after a meal. The trial, which recruited 24 type 1 diabetics, studied the effect of Adocia’s BioChaperone pramlintide insulin on glucose levels right after […] September 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2018 Cassava Plants Gene Edited Using CRISPR to Produce Waxy Starch A team of European researchers applied CRISPR-Cas9 gene editing technology to engineer cassava plants that produce a modified type of starch, in demand for both cooking and industrial processing. The team also managed to speed up the flowering of the plants by introduction of a gene from Arabidopsis plants, which they hope will allow more […] September 5, 2018 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2018 RNA Therapy Improves Vision in Patients with Rare Genetic Blindness Dutch company ProQR has released data from a Phase I/II trial showing its RNA therapy can improve the vision of people with a rare form of hereditary blindness. The clinical trial recruited 10 people with the rare disease Leber’s congenital amaurosis 10. Caused by mutations in a gene called CEP290, this condition leads to […] September 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Sep 2018 The EMA Approves the First Nanobody from Ablynx Update: The EMA has officially approved Cablivi for the treatment of adults with acquired thrombotic thrombocytopenic purpura, following its earlier recommendation in June. The drug has also been accepted for priority review by the US FDA, with a decision due on 6 Feb 2019. Published 29.6.18 Just a few months after Sanofi acquired Ablynx in a multi-billion euro […] September 4, 2018 - 2 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 3 Sep 2018 Oxford Biotech Raises €40M to Deliver Drugs to Hard-to-Reach Targets Evox Therapeutics has raised £35.5M (€39.4M) in a Series B fundraising that has been backed, among others, by the venture arm of Google’s parent company. A spin-out from the University of Oxford and the Karolinska Institute, Evox Therapeutics has raised a large round that will fund the development of its drug delivery technology to […] September 3, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2018 A Symphony Inspired by the Microbes Living on Us British artist Victoria Shennan has created a musical composition based on the microorganisms that form an essential part of us. We are just starting to realize the huge role that microorganisms play in our well-being and the proper functioning of our bodies. Research on the human microbiome in the last decade has linked the […] September 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2018 Vertex Partners Oxford Genome Analysis Firm To Develop New Personalized Therapies Genomics, a company using machine learning to analyze genetic data, is partnering with precision medicine specialists Vertex Pharmaceuticals to develop new therapies in a 3-year collaboration. The agreement marks the closing of the Oxford-based company’s €28M (£25M) series B fundraising round, as Vertex has also invested €11.7M (£10.5M) in Genomics. If the collaboration is successful […] August 31, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2018 First RNAi Drug Approved in Europe After 20 Years of Research The first ever RNA interference (RNAi) drug, used to treat polyneuropathy in patients with hereditary transthyretin-mediated amyloidosis, has been given marketing approval by the European Commision. The approval follows that of the US FDA who gave the green light to US biotech Alnylam Pharmaceutical’s Onpattro (patisiran) earlier this month following positive Phase III findings in […] August 30, 2018 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email